Project Grant R01AI182159
Award Date
8/16/24
Completion Date
6/30/29
Dollars Obligated
$1.5M
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Nashville, TN 37203, USA
Similar Awards
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $2,888,757 to the University of Arizona to conduct research on a novel therapeutic approach for asthma treatment. The central focus is investigating the roles of protease-activated receptor-2 (PAR2) signaling in airway epithelial cells and sensory neurons, and evaluating the potential of small molecule PAR2 antagonists...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $730,392 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of Colorado-Denver. The 5-year grant, awarded on Jun 17, 2025, supports research to investigate the role of adipose tissue and adipose eosinophils in regulating airway function and inflammation in lean and obese mouse models of asthma. The key objectives are to: 1) Determine the metabolic response of...
This Project Grant award of $185,866 from the National Institute of Allergy and Infectious Diseases (NIAID) under CFDA 93.855 - Allergy and Infectious Diseases Research supports research to investigate the role of syndecan-1 (SDC1) cleavage in driving inflammation and steroid resistance in a preclinical model of severe allergic asthma. The research aims to evaluate the effects of macrophage-derived heparanase activity on airway epithelial SDC1 cleavage, and determine if the plant-derived...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $175,000 to the La Jolla Institute for Immunology to conduct research on the role of Alternaria fungal sensitization in asthma pathogenesis. The research aims to explore the mechanisms and cell types that drive Alternaria sensitization and the development of asthma. Key activities include: Determining the association...
This Project Grant award for $355,935 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research federal grant program (CFDA 93.837) supports the development of a novel, oral immunoregulatory therapeutic for the treatment of asthma. The primary objectives are to characterize the therapeutic efficacy and dosing regimen of the compound in mouse models of asthma, and to evaluate its ability to modulate immune function and suppress inflammation in human...
This Project Grant award of $387,116 from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research at the University of South Florida to investigate the mechanisms underlying house dust mite-induced airway hyperreactivity, a key symptom of asthma. The research aims to define the specific sensory nerve populations and signaling pathways triggered by house dust mite exposure that lead to the development of airway hyperreactivity, in order to...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to develop a bifunctional IgE antagonist and dissociator (ANDI) drug for treating severe allergic asthma. The $320,863 award to Aaiit LLC aims to advance ANDI, a novel protein-based therapeutic that can both antagonize and dissociate IgE bound to mast cell receptors. This is intended to complement the existing...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $590,711 in funding to the University of Southern California (USC) to study the role of the ICOS costimulatory molecule on group 2 innate lymphoid cells (ILC2s) and their potential to regulate allergic asthma. The key objectives are to: 1) Determine the necessity of specific transcription factors in IL-10 production by...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $597,904 to the University of Wisconsin - Madison to conduct research on the role of the human microbiome and its interactions with host genetics in childhood asthma. The research aims to: 1) detect host genome-wide associations with the infant microbiome, 2) identify genotype-microbiome interaction effects on...
This federal Project Grant award of $613,934 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research into the role of the aryl hydrocarbon receptor (AhR) signaling pathway in regulating airway smooth muscle responses during inflammation and asthma. The key objectives are to: 1) Determine the mechanisms of AhR expression and regulation in human airway smooth muscle under inflammatory conditions; 2) Investigate...